MXPA05012323A - Sulfonamidas ciclicas para la inhibicion de gama-secretasa. - Google Patents

Sulfonamidas ciclicas para la inhibicion de gama-secretasa.

Info

Publication number
MXPA05012323A
MXPA05012323A MXPA05012323A MXPA05012323A MXPA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A
Authority
MX
Mexico
Prior art keywords
secretase
gamma
inhibition
cyclic sulfonamides
sulfonamides
Prior art date
Application number
MXPA05012323A
Other languages
English (en)
Inventor
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311341A external-priority patent/GB0311341D0/en
Priority claimed from GB0327055A external-priority patent/GB0327055D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MXPA05012323A publication Critical patent/MXPA05012323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Los compuestos de la formula (I) (ver formula I) inhiben el procesamiento de APP a traves de gamma-secretasa, y por lo tanto son utiles en el tratamiento o prevencion de la enfermedad de Alzheimer.
MXPA05012323A 2003-05-16 2004-05-07 Sulfonamidas ciclicas para la inhibicion de gama-secretasa. MXPA05012323A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0311341A GB0311341D0 (en) 2003-05-16 2003-05-16 Therapeutic agents
GB0327055A GB0327055D0 (en) 2003-11-20 2003-11-20 Therapeutic agents
PCT/GB2004/002013 WO2004101539A1 (en) 2003-05-16 2004-05-07 Cyclic sulfonamides for inhibition of gamma-secretase

Publications (1)

Publication Number Publication Date
MXPA05012323A true MXPA05012323A (es) 2006-01-30

Family

ID=33420897

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012323A MXPA05012323A (es) 2003-05-16 2004-05-07 Sulfonamidas ciclicas para la inhibicion de gama-secretasa.

Country Status (16)

Country Link
US (3) US7410964B2 (es)
EP (2) EP1644346A1 (es)
JP (1) JP4818114B2 (es)
KR (1) KR20060013404A (es)
AT (1) ATE386028T1 (es)
AU (1) AU2004238607B2 (es)
BR (1) BRPI0409969A (es)
CA (1) CA2525841C (es)
DE (1) DE602004011767T2 (es)
IL (1) IL171977A (es)
IS (1) IS8058A (es)
MX (1) MXPA05012323A (es)
NO (1) NO20055979L (es)
NZ (1) NZ542797A (es)
RU (1) RU2334743C2 (es)
WO (2) WO2004101539A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7410964B2 (en) * 2003-05-16 2008-08-12 Merck Sharp & Dohme Ltd. Cyclohexyl sulphones as gamma-secretase inhibitors
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP1888078A2 (en) * 2005-05-17 2008-02-20 Merck Sharp & Dohme Ltd. Sulphone derivatives for treatment of cancer
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
GB0512049D0 (en) * 2005-06-14 2005-07-20 Merck Sharp & Dohme Chemical process
RU2448964C2 (ru) * 2006-01-20 2012-04-27 Шеринг Корпорейшн КАРБОЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ АРИЛСУЛЬФОНЫ, ИХ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ОБЛАДАЮЩАЯ СВОЙСТВАМИ ИНГИБИТОРА γ-СЕКРЕТАЗЫ
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
JP5240871B2 (ja) * 2007-07-05 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション テトラヒドロピラノクロメンガンマセレクターゼ阻害剤
KR20100044840A (ko) 2007-07-17 2010-04-30 쉐링 코포레이션 벤젠설포닐-크로만, 티오크로만, 테트라하이드로나프탈렌 및 관련 감마 세크레타제 억제제
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20110263580A1 (en) * 2008-12-11 2011-10-27 Thomas Miller Method for treating alzheimer's disease and related conditions
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011092611A1 (en) * 2010-01-29 2011-08-04 Pfizer Inc. Aminocyclohexanes and aminotetrahydropyrans and related compounds as gamma-secretase modulators
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020408148A1 (en) 2019-12-17 2022-06-16 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2022015670A1 (en) * 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833776A (en) * 1958-05-06 Aryl-substituted psperidylpropanols
US3992536A (en) * 1972-11-11 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use
US3869434A (en) * 1973-11-19 1975-03-04 Phillips Petroleum Co Soluble arylene sulfide polymers
DE2528285A1 (de) * 1975-06-25 1977-01-20 Basf Ag Verfahren zur herstellung von 1,2,4-dihydrotriazin-4-oxid-spiro- (3,1')- eckige klammer auf oximino- (2')-cycloalkanen eckige klammer zu
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU773273B2 (en) 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
JP2003528076A (ja) * 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
FR2812291B1 (fr) * 2000-07-28 2002-12-13 Adir Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2427206C (en) 2000-11-02 2011-06-28 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108592D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
US7410964B2 (en) 2003-05-16 2008-08-12 Merck Sharp & Dohme Ltd. Cyclohexyl sulphones as gamma-secretase inhibitors

Also Published As

Publication number Publication date
AU2004238607A1 (en) 2004-11-25
WO2004101538A1 (en) 2004-11-25
NZ542797A (en) 2007-12-21
KR20060013404A (ko) 2006-02-09
US20040230054A1 (en) 2004-11-18
RU2334743C2 (ru) 2008-09-27
DE602004011767T2 (de) 2009-02-19
EP1638951A1 (en) 2006-03-29
AU2004238607B2 (en) 2010-05-27
NO20055979L (no) 2006-02-15
BRPI0409969A (pt) 2006-04-25
US7342009B2 (en) 2008-03-11
EP1644346A1 (en) 2006-04-12
US20080045515A1 (en) 2008-02-21
CA2525841A1 (en) 2004-11-25
WO2004101539A1 (en) 2004-11-25
IL171977A0 (en) 2006-04-10
DE602004011767D1 (de) 2008-03-27
CA2525841C (en) 2012-10-16
ATE386028T1 (de) 2008-03-15
IL171977A (en) 2010-12-30
JP2006528961A (ja) 2006-12-28
US20060281737A1 (en) 2006-12-14
US7410964B2 (en) 2008-08-12
JP4818114B2 (ja) 2011-11-16
RU2005139398A (ru) 2006-04-10
EP1638951B1 (en) 2008-02-13
IS8058A (is) 2005-09-30

Similar Documents

Publication Publication Date Title
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0318447D0 (en) Therapeutic agents
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
AU1074702A (en) Sulfamides as gamma-secretase inhibitors
GB0225475D0 (en) Therapeutic agents
GB0225474D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
RS8504A (en) Novel cyclohexil sulphones
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase
TW200503672A (en) 2-aminobenzoyl derivatives

Legal Events

Date Code Title Description
FG Grant or registration